Implications of the U.S. Food and Drug Administration Warning against the Use of Sildenafil for the...
Implications of the U.S. Food and Drug Administration Warning against the Use of Sildenafil for the Treatment of Pediatric Pulmonary Hypertension
About this item
Full title
Author / Creator
Publisher
New York, NY: American Thoracic Society
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: American Thoracic Society
Subjects
More information
Scope and Contents
Contents
Pulmonary arterial hypertension (PAH) contributes to disability and death in children with diverse cardiac, pulmonary, or systemic diseases, and therapeutic options are currently limited. Data from adult studies provide the basis for most PAH-specific therapies; however, many of these medications are commonly used in children on an off-label basis...
Alternative Titles
Full title
Implications of the U.S. Food and Drug Administration Warning against the Use of Sildenafil for the Treatment of Pediatric Pulmonary Hypertension
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1317855695
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1317855695
Other Identifiers
ISSN
1073-449X
E-ISSN
1535-4970
DOI
10.1164/rccm.201210-1928pp
